Hydroxychloroquine does not counter SARS-CoV-2 in hamsters, high dose of favipiravir does
KU Leuven
A high dose of the anti-flu drug favipiravir, by
contrast, has an antiviral effect in the hamsters. The team published their
findings in the Proceedings of the National Academy of Sciences (PNAS).
Virologists
at the KU Leuven Rega Institute have been working on two lines of SARS-CoV-2
research: searching for a vaccine to prevent infection, and testing existing
drugs to see which one can reduce the amount of virus in infected people.
To test the efficacy of the vaccine and antivirals preclinically, the researchers use hamsters. The rodents are particularly suitable for SARS-CoV-2 research because the virus replicates itself strongly in hamsters after infection.
Moreover, hamsters develop a lung pathology similar to mild COVID-19 in humans.
This is not the case with mice, for example.
For this study, the team of Suzanne Kaptein (PhD), Joana Rocha-Pereira (PhD), Professor Leen Delang, and Professor Johan Neyts gave the hamsters either hydroxychloroquine or favipiravir -- a broad-spectrum antiviral drug used in Japan to treat influenza -- for four to five days.
They tested several doses of favipiravir. The hamsters were infected with the SARS-CoV-2 virus in two ways: by inserting a high dose of virus directly into their noses or by putting a healthy hamster in a cage with an infected hamster.
Drug treatment was started
one hour before the direct infection or one day before the exposure to an
infected hamster. Four days after infection or exposure, the researchers
measured how much of the virus was present in the hamsters.
Hydroxychloroquine
versus favipiravir
Treatment with hydroxychloroquine had no impact: the virus levels did not decrease and the hamsters were still infectious. "Despite the lack of clear evidence in animal models or clinical studies, many COVID-19 patients have already been treated with hydroxychloroquine," explains Joana Rocha-Pereira.
"Based on these results and the results of other teams, we advise against
further exploring the use of hydroxychloroquine as a treatment against
COVID-19."
A high dose of favipiravir, however, had a potent effect. A few days after the infection, the virologists detected hardly any infectious virus particles in the hamsters that received this dose and that had been infected intranasally.
Moreover, hamsters that were in a cage with an infected hamster and had been
given the drug did not develop an obvious infection. Those that had not received
the drug all became infected after having shared a cage with an infected
hamster.
A
low dose of the drug favipiravir did not have this outcome. "Other studies
that used a lower dose had similar results," Professor Delang notes.
"The high dose is what makes the difference. That's important to know,
because several clinical trials have already been set up to test favipiravir on
humans."
Cautious
optimism
The
researchers are cautiously optimistic about favipiravir. "Because we
administered the drug shortly before exposing the hamsters to the virus, we
could establish that the medicine can also be used prophylactically, so in
prevention," Suzanne Kaptein notes.
"If
further research shows that the results are the same in humans, the drug could
be used right after someone from a high-risk group has come into contact with
an infected person. It may likely also be active during the early stages of the
disease."
General
preventive use is probably not an option, however, because it is not known
whether long-term use, especially at a high dose, has side effects.
No
panacea
Further
research will have to determine whether humans can tolerate a high dose of
favipiravir. "In the hamsters, we detected hardly any side effects,"
says Delang. In the past, the drug has already been prescribed in high doses to
Ebola patients, who appear to have tolerated it well.
"Favipiravir
is not a panacea," the researchers warn. This flu drug, nor any other
drug, has not been specifically developed against coronaviruses. As a result,
the potency of favipiravir is to be considered moderate at best.
The study also highlights the importance of using small animals to test therapies against SARS-CoV-2 in vivo. "Our hamster model is ideally suited to identify which new or existing drugs may be considered for clinical studies," explains Professor Johan Neyts. "In the early days of the pandemic, such a model was not yet available.
At that time, the only option was
to explore in patients whether or not a drug such as hydroxychloroquine could
help them. However, testing treatments on hamsters provides crucial information
that can prevent the loss of valuable time and energy with clinical trials on
drugs that don't work."
Not
all research models are equal
Kaptein, Rocha-Pereira, Delang and Neyts recently contributed to a commentary in Nature Communications in which they give additional context to the contradictory messages that have been circulating about (hydroxy)chloroquine.
In the early days of the pandemic, several studies were set up to test these
drugs in cell cultures. The results suggested that they could have an antiviral
effect. As a result, clinical trials were organised to test the drugs on
humans. However, cell cultures are not the best proxy for the human body, and
no conclusive effect was found in humans.
In
their commentary, the authors describe several recent studies on human
organ-on-chip and other complex in vitro models, mice, hamsters, and non-human
primates. Each of these studies demonstrates that hydroxychloroquine and
chloroquine do not have the efficacy suggested by the studies in cell cultures.
Therefore, the authors conclude that these malaria drugs are very unlikely to
be effective in humans as a COVID-19 treatment.
More
information
The
study "Favipiravir at high doses has potent antiviral activity in
SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity"
by Suzanne Kaptein, Johan Neyts, Joana Rocha-Pereira, Leen Delang et al.
was published in PNAS.
The
commentary "Emerging preclinical evidence does not support broad use of
hydroxychloroquine in COVID-19 patients" by Funnell et al. was
published in Nature Communications (open access).
